Search

The lepidopteran herbivore Secusio extensa (Erebidae: Arctiinae) was purposefully released in Hawaii in 2013 to control Madagascar fireweed, Senecio madagascariensis (Asteraceae: Senecioneae), an invasive weed of rangelands and other open areas. In conjunction with this biocontrol effort, we conducted pre- and post-release monitoring of S. madagascariensis in field plots, and post-release monitoring of non-target plants. Secusio extensa successfully established on the two islands where it was released, dispersed widely, and even colonized a neighboring island. However, in the first three years after release, S. extensa could only be found sporadically and in low abundances on its target host. In contrast, it underwent population outbreaks on the related, alternative host, Cape ivy (Delairea odorata, Asteraceae: Senecioneae), which is also a noxious weed in Hawaii. In addition to D. odorata, we observed S. extensa to feed on only two other related non-target plants in the tribe Senecioneae, among 24 species monitored. In several microsites supporting higher densities of S. extensa on S. madagascariensis, larval abundances peaked during a short period in the spring, but were insufficiently high to cause substantial damage to affected plants. The causes for low larval densities of S. extensa on its target host are unclear. We found no strong evidence for parasitism or predation of S. extensa larvae. However, females preferred to oviposit on D. odorata over S. madagascariensis, and larvae exhibited a marginally significant preference for feeding on D. odorata over S. madagascariensis. This preference, along with lower nutritional quality of S. madagascariensis relative to D. odorata, may explain why S. extensa has been unable to build large populations on its intended target, but has done so on an alternate host. Clarifying the roles of these mechanisms may help predict the continuing performance of S. extensa in controlling S. madagascariensis.

This article explores the historical antecedents to the Russian anecdote which remarks on the reactions by various nationalities’ to finding a fly in their soup and considers the function of such anecdotes in their popular usage.

Next-generation nuclear astrophysics investigations must address a demanding set of requirements to probe the matter and energy life-cycle in our Galaxy and throughout the Cosmos. Enhanced flux sensitivity and (near) all-sky monitoring are just two of these requirements; cost effectiveness and other programmatic restrictions pose additional challenges. These competing goals can be addressed with a paradigm change, i.e. performing investigations from lunar orbit and utilizing a new detection and imaging technique. We report on our development of the Moon as a platform for nuclear astrophysics utilizing the Lunar Occultation Technique (LOT). Here source fluxes are temporally modulated as they are repeatedly occulted by the Moon; the modulation, as observed by a suitably configured instrument in lunar orbit, enables the detection, imaging, and characterization of both point- and extended-sources, narrow-line and broadband sources. Key benefits include maximizing the ratio of sensitive-to-total deployed mass and the operational simplicity relative to other detection schemes. A mission based on the LOT, the Lunar Occultation Explorer (LOX), will be the first to employ occultation as the principle method to characterize the intensity, variability, and spectra of detected sources.

Summary BP and Maersk Drilling entered into a unique collaborative arrangement in early 2013 to develop the design for a deepwater drilling rig that is specifically aimed at conducting operations on wells with greater than 15,000 psi pressures. This paper describes how this collaborative effort was conducted. Operator and contractor each contributed expertise and information to the project and defined a joint vision of transforming how functional requirements are set and how the design of this rig would be developed. A set of relationship principles was agreed and a joint project team was formed in Houston with engineering support from contrator's technical organization in Copenhagen. An executive committee, with senior leadership from each organization, was established to provide guidance, challenge and governance. To start the design process, workflow during the well construction process was layered on top of the foundational requirements of operator's prospect inventory. Starting with a cleaner sheet of paper, the integrated team's conversations focused on inherently safer design and improving operability, efficiency, maintainability and reliability. The initial focus was on innovation and possibilities before driving toward agreement on the functional specification and rig design. The team strove to address challenges faced in the deepwater drilling industry today, at the same time continually testing their ideas for benefit. After more definition work, the opportunities were run through a detailed evaluation model to inform selection of design features and potential equipment suppliers. Major equipment suppliers and operator service companies have assisted with the development of rig functional requirements and the shipyard specification. Operator and contractor contributed their learning from previous rig builds, intakes and operation including five and ten year re-certifications into the design. Supplier selection for long lead technology development and qualification of equipment commenced in 2013 and is expected to culminate with a yard selection in 2015. As a result of this collaboration, operator and contractor better understand the needs and drivers of each other's business and have leveraged this knowledge into a more effective working relationship. Significant work remains to construct the rig and deliver it into operation. However, there is a strong belief this next generation deepwater drilling rig will provide enhanced capability, performance and value to both operator and contractor.

Layered nanoparticles have the potential to deliver any number of substances to cells both in vitro and in vivo. The purpose of this study was to develop and test a relatively simple alternative to custom synthesized nanoparticles for use in multiple biological systems, with special focus on the eye.The biotin-labeled transcriptionally active PCR products (TAP) were conjugated to gold, semiconductor nanocrystals, and magnetic nanoparticles (MNP) coated with streptavidin. The process of nanoparticle construction was monitored with gel electrophoresis. Fluorescence microscopy followed by image analysis was used to examine gene expression levels from DNA alone and tethered MNP in human hepatoma derived Huh-7 cells. Adult retinal endothelial cells from both dog (ADREC) and human (HREC) sources were transfected with nanoparticles and reporter gene expression evaluated with confocal and fluorescent microscopy. Transmission electron microscopy was used to quantify the concentration of nanoparticles in a stock solution. Nanoparticles were evaluated for transfection efficiency, determined by fluorescence microscopy cell counts. Cells treated with MNP were evaluated for increased reactive oxygen species (ROS) and necrosis with flow cytometry.Both 5' and 3' biotin-labeled TAP bound equally to MNP and there were no differences in functionality between the two tethering orientations. Free DNA was easily removed by the use of magnetic columns. These particles were also able to deliver genes to a human hepatoma cell line, Huh-7, but transfection efficiency was greater than TAP. The semiconductor nanocrystals and MNP had the highest transfection efficiencies. The MNP did not induce ROS formation or necrosis after 48 h of incubation.Once transfected, the MNP had reporter gene expression levels equivalent to TAP. The nanoparticles, however, had better transfection efficiencies than TAP. The magnetic nanoparticles were the most easily purified of all the nanoparticles tested. This strategy for bioconjugating TAP to nanoparticles is valuable because nanoparticle composition can be changed and the system optimized quickly. Since endothelial cells take up MNP, this strategy could be used to target neovascularization as occurs in proliferative retinopathies. Multiple cell types were used to test this technology and in each the nanoparticles were capable of transfection. In adult endothelial cells the MNP appeared innocuous, even at the highest doses tested with respect to ROS and necrosis. This technology has the potential to be used as more than just a vector for gene transfer, because each layer has the potential to perform its own unique function and then degrade to expose the next functional layer.

We previously described a population of lymphoid progenitor cells (LPCs) in canine B-cell lymphoma defined by retention of the early progenitor markers CD34 and CD117 and “slow proliferation” molecular signatures that persist in the xenotransplantation setting. We examined whether valspodar, a selective inhibitor of the ATP binding cassette B1 transporter (ABCB1, a.k.a., p-glycoprotein/multidrug resistance protein-1) used in the neoadjuvant setting would sensitize LPCs to doxorubicin and extend the length of remission in dogs with therapy naïve large B-cell lymphoma. Twenty dogs were enrolled into a double-blinded, placebo controlled study where experimental and control groups received oral valspodar (7.5 mg/kg) or placebo, respectively, twice daily for five days followed by five treatments with doxorubicin 21 days apart with a reduction in the first dose to mitigate the potential side effects of ABCB1 inhibition. Lymph node and blood LPCs were quantified at diagnosis, on the fourth day of neoadjuvant period, and 1-week after the first chemotherapy dose. Valspodar therapy was well tolerated. There were no differences between groups in total LPCs in lymph nodes or peripheral blood, nor in event-free survival or overall survival. Overall, we conclude that valspodar can be administered safely in the neoadjuvant setting for canine B-cell lymphoma; however, its use to attenuate ABCB1+ cells does not alter the composition of lymph node or blood LPCs, and it does not appear to be sufficient to prolong doxorubicin-dependent remissions in this setting.

The success of parole programs is perceived as dependent upon administrative organization, qualifications of parole board members and parole officers, parole granting policies, caseload size, and costs. A survey of these factors in the United States shows wide variation among jurisdictions. Some jurisdictions have no specified qualifications for parole board members, while others require several years of responsible correctional service. Qualifirations required of parole officers were found to be, in general, neither high nor rigid. Caseloads were found to range from twenty-four to 167, with a median of approximately seventy-seven. The median cost of parole supervision was found to be $.47 per day per parolee.